Skip to main content
Figure 3 | Molecular Cancer

Figure 3

From: Panobinostat reduces hypoxia-induced cisplatin resistance of non-small cell lung carcinoma cells via HIF-1α destabilization

Figure 3

Effects of co-treatment with cisplatin and panobinostat on cell viability. (A) Cells were treated with 16 μM cisplatin or 16 nM panobinostat alone and with combination of both substances for 24 and 48 hours. Afterwards cell viability was determined with the AlamarBlue® assay (n ≥ 6 measurements per each condition). DMSO was used as a vehicle control and all results were compared to DMSO-treated cells set to 100%. (B) H23 cells were treated with 0.2 μM and 1 μM LMK235 (N-((6-(hydroxyamino)-6-oxohexyl)oxy)-3,5-dimethylbenzamide) alone and in combination with cisplatin for 24 and 48 hours. LMK235 is a new HDAC inhibitor selective towards human HDAC4 and 5. Cell viability was determined with AlamarBlue® assay and results from three independent experiments (n = 4 measurements per each condition) were compared to DMSO-treated cells set to 100%. NOX, normoxia; HOX, hypoxia; ns, not significant; * P < 0.05; ** P < 0.01; *** P < 0.001; determined by Student’s t-test. Pano, panobinostat; Cis, cisplatin.

Back to article page

Molecular Cancer

ISSN: 1476-4598